What If Treatment Meant Six Appointments a Year, Not 365 Pills?
For most of the HIV epidemic's history, effective treatment has meant a daily commitment: swallowing one or more pills, every day, for life. That regimen works, but daily adherence is hard to sustain indefinitely, and missed doses can allow the virus to rebound or develop resistance. Long-acting injectable antiretroviral therapy changes the shape of that commitment. Instead of a daily ritual, a person receives an intramuscular injection from a clinician on a fixed schedule, and the drug slowly releases into the bloodstream between visits.
The first regimen to reach this milestone combines cabotegravir and rilpivirine, marketed as Cabenuva and developed through research supported by ViiV Healthcare and Janssen Pharmaceuticals. The U.S. Food and Drug Administration approved it for adults with an undetectable viral load who are already stable on oral therapy. After an initial oral lead-in period to check tolerability, patients transition to injections given monthly or, for many, every two months.
Who Benefits, and What the Trade-offs Are
Clinical trials such as ATLAS and FLAIR, which supported approval, found that long-acting injectable therapy was as effective as standard oral regimens at maintaining viral suppression. The appeal goes beyond convenience. For people who find daily pill-taking psychologically burdensome, a reminder of their diagnosis at every dose, or who worry about medication visibility to family or coworkers, an injection every one to two months can reduce that daily friction. Researchers and clinicians, including those tracking outcomes through the Centers for Disease Control and Prevention, note that adherence is one of the strongest predictors of long-term treatment success, so any tool that makes sustained adherence easier has real clinical value.
The approach is not without limits. Injection-site reactions, such as pain, swelling, or firmness at the injection site, are common, though usually mild and temporary. Because the drug clears slowly from the body over months, missing or delaying a scheduled visit carries different risks than missing a single pill, so candidates need reliable access to a clinic and a care team comfortable managing those logistics. It is generally reserved for people who are already virally suppressed on oral therapy, not as a starting regimen for someone newly diagnosed.
Beyond the cabotegravir-rilpivirine combination, researchers are studying longer-interval formulations and injectable options that could stretch dosing to every four months or beyond, along with implantable devices that release medication continuously. Investigators at institutions including Johns Hopkins University have highlighted how these advances could particularly help people for whom daily adherence has been a persistent barrier, including some adolescents, people experiencing housing instability, and those managing complex comorbid conditions. As the toolkit of HIV treatment options expands, the underlying goal remains the same one that has guided care since the advent of effective combination therapy: helping people living with HIV maintain an undetectable viral load, protect their long-term health, and prevent transmission to others.
This article is general information gathered from reputable public sources — not a substitute for advice from a qualified healthcare provider.